Gilead Preps HCV Sales Force For Sofosbuvir Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The virology-focused company has been considering pricing strategies and building its U.S. sales force in anticipation of an approval for its nucleoside polymerase inhibitor.